BriaCell Therapeutics Corp. BCTX · Stock Open BriaCell Therapeutics Corp. in new tab
BriaCell Therapeutics Corp. Analysis (BCTX)
Is BriaCell Therapeutics Corp. a good investment? BriaCell Therapeutics Corp. (BCTX) is currently trading at 4.11 USD.
Investor FAQ
Does BriaCell Therapeutics Corp. pay a dividend?
No, it does not currently pay a dividend.
What asset class is BriaCell Therapeutics Corp.?
BriaCell Therapeutics Corp. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
| Split Date | Split Ratio to 1 |
|---|---|
| Dec. 3, 2014 | 0.307 |
| Jan. 2, 2020 | 1:300 |
| Jan. 29, 2025 | 1:15 |
| Aug. 25, 2025 | 1:10 |
Community Discussion